Solti

Recent papers from Solti

1. Rationale and trial design of RIBOLARIS: A phase II trial of neoadjuvant and adjuvant ribociclib plus endocrine therapy for clinically high-risk HR+/HER2-negative breast cancerTherapeutic Advances in Medical Oncology · 2026
2. Preoperative onapristone-XR in postmenopausal women with progesterone receptor-positive (PgR+)/HER2-negative early breast cancer: SOLTI-1802 ONAWA trial resultsnpj Breast Cancer · 2026
3. 129eP Tumor-infiltrating lymphocytes (TILs) dynamics in breast cancer diagnosed during (PrBC): A monocentric exploratory analysis before and after neoadjuvant chemotherapy (NACT)ESMO Open · 2026
4. Neoadjuvant palbociclib and endocrine therapy versus chemotherapy in ER + /HER2- breast cancer: a randomized phase II trialNature Communications · 2026
5. Dynamic biomarkers in hormone receptor-positive/HER2-negative breast cancer trials: a new hope for precision oncologynpj Breast Cancer · 2026
6. Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT studyBreast Cancer Research and Treatment · 2026
7. Talimogene laherparepvec and atezolizumab in HER2-negative breast cancer following neoadjuvant chemotherapy: a window-of-opportunity phase II trial (SOLTI-1503 PROMETEO)Nature Communications · 2026
8. Abstract PS4-01-07: Prospective Validation of HER2DX in Early HER2+ Breast Cancer: Operational Feasibility of Centralized Genomic Screening in the DEFINITIVE Trial. Real-Time Insights from the First 80 Screened PatientsClinical Cancer Research · 2026
9. CAR T-cell therapy in patients with acute lymphoblastic leukemia: a systematic review and meta-analysisBone Marrow Transplantation · 2026
10. Pembrolizumab and Paclitaxel in HR+/HER2− Breast Cancer with HER2-Enriched or Basal-Like SubtypesClinical Cancer Research · 2026
11. Enhancing Clinical Cancer Research Through Sharing of Data and BiospecimensJAMA Oncology · 2025
12. Addition of ipatasertib to dual anti-HER2 maintenance therapy in HER2-positive metastatic breast tumors with PIK3CA mutations: the phase 1b SOLTI-1507 IPATHER trialClinical Cancer Research · 2025
13. Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trialClinical Cancer Research · 2025
14. Palbociclib, trastuzumab and endocrine therapy in pretreated HER2-positive and PAM50 luminal advanced breast cancer: randomised phase II, SOLTI-1303 PATRICIA trialClinical Cancer Research · 2025
15. Endocrine-based strategies after CDK4/6 inhibitors in biomarker-selected subgroup of hormone receptor positive advanced breast cancer: A systematic review and network meta-analysisCancer Treatment Reviews · 2025
16. Efficacy of anti-PD1 therapy in PD1-high mRNA tumors across multiple cancer types: results from cohort 1 and cohort 2 of the phase II SOLTI-1904 ACROPOLI trialESMO Open · 2025
17. Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNEBMJ Open · 2025
18. Palbociclib and trastuzumab for HER2-positive metastatic breast cancer: final overall survival results of cohort A and B of SOLTI-1303-PATRICIA trialESMO Open · 2025
19. Transcriptomic Predictors of Survival for Palbociclib + Endocrine Therapy Versus Capecitabine in Aromatase Inhibitor–Resistant Breast Cancer From the GEICAM/2013-02 PEARL TrialJCO Precision Oncology · 2025
20. Stromal tumor infiltrating lymphocytes and TNBC-DX provide complementary prognostic information in triple-negative breast cancerJNCI Journal of the National Cancer Institute · 2025